Immediate Impact
1 standout
Citing Papers
Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management
2023 Standout
Works of Allison M. Booth being referenced
Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
2019
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Allison M. Booth | 14 | 10 | 9 | 6 | 21 | |
| M Sopena | 13 | 5 | 15 | 7 | 23 | |
| Elisabeth Brottier-Mancini | 19 | 10 | 10 | 5 | 25 | |
| Kaitlin Kennard | 15 | 15 | 8 | 9 | 25 | |
| Zoltán Gasztonyi | 10 | 8 | 16 | 7 | 22 | |
| Janet Schmid | 9 | 9 | 5 | 6 | 15 | |
| Aoife Gatenby | 11 | 9 | 12 | 6 | 29 | |
| I. Serriello | 12 | 7 | 5 | 4 | 19 | |
| Rüdiger Liersch | 10 | 7 | 5 | 4 | 22 | |
| Giulia Palazzo | 9 | 12 | 14 | 6 | 33 | |
| Barbara Forno | 9 | 4 | 23 | 6 | 30 |
All Works
Loading papers...